Back

Troponin and NTproPNB levels before starting cancer therapy with immune checkpoint inhibitors can predict all-cause mortality

20 June 2026 (10:45 - 11:45)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology insights into immunity and immune checkpoint inhibitors Cancer Biology and Treatment Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Professor Sebastian Szmit

CMKP & National Research Institute of Oncology, Warsaw (Poland)

8 More presentations in this session

Presentation thumbnail
VISTA, a next-generation immune checkpoint: expression in heart failure and cardiovascular safety of inhibition
Doctor M. Jakab (Budapest, HU)
Abstract Slides
Presentation thumbnail
Angiotensin II unmasks immune checkpoint inhibitor-induced arrhythmias and conduction defects in mice
Doctor A. Ramalingam (Budapest, HU)
Abstract Slides
Presentation thumbnail
Immune checkpoint inhibitor-induced alterations in thymic gene expression and spatial distribution
Doctor A. Kulin (Budapest, HU)
Abstract Slides
Presentation thumbnail
Immune checkpoint inhibitors induce immune-mediated myocarditis and inflammasome activation in a tumor-bearing mouse model
Mr S. Lledo (Marseille, FR)
Abstract Slides
Presentation thumbnail
Myeloid cell leukemia 1 inhibition triggers a transient cardiac stress signature in a humanized mouse model
Doctor M. Heckmann (Heidelberg, DE)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology insights into immunity and immune checkpoint inhibitors

The Event

Event poster

ESC Cardio-Oncology 2026

20 June 2026 10:45 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources